Abstract
IntroductionThe introduction of biosimilar infliximab with CT-P13 offers substantial potential cost savings. Data on switching from Remicade to CT-P13 is only just emerging and was not available in early 2016....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
